Gene signature for immune therapies in cancer
An immune response subtype of cancer is associated with DNA damage which allows subjects to be stratified for particular therapies including immune therapies which may be combined with DNA damage therapeutics. A method for predicting responsiveness to an antagonist of an inhibitory immune checkpoint...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Kennedy, Richard Hill, Laura A Deharo, Steve Walker, Steven Parkes, Eileen Keating, Katherine E O'Donnell, Jude Patterson, Fionnuala Harkin, Denis Paul Davison, Timothy Goffard, Nicolas Bylesjo, Max Proutski, Vitali Taggart, Laura |
| description | An immune response subtype of cancer is associated with DNA damage which allows subjects to be stratified for particular therapies including immune therapies which may be combined with DNA damage therapeutics. A method for predicting responsiveness to an antagonist of an inhibitory immune checkpoint and/or an agonist of a stimulatory immune checkpoint comprises determining the expression level of at least one gene selected from Table 2B, 2A or 1 in a sample from the subject. The determined expression level is used to predict responsiveness to an antagonist of an inhibitory immune checkpoint and/or an agonist of a stimulatory immune checkpoint. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_AU2016295347A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>AU2016295347A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_AU2016295347A13</originalsourceid><addsrcrecordid>eNrjZNB1T81LVSjOTM9LLCktSlVIyy9SyMzNLQUKlmSkFiUWZKYWK2TmKSQn5iWnFvEwsKYl5hSn8kJpbgZlN9cQZw_d1IL8-NTigsRkoGkl8Y6hRgaGZkaWpsYm5o6GxsSpAgBbYyrd</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Gene signature for immune therapies in cancer</title><source>esp@cenet</source><creator>Kennedy, Richard ; Hill, Laura A ; Deharo, Steve ; Walker, Steven ; Parkes, Eileen ; Keating, Katherine E ; O'Donnell, Jude ; Patterson, Fionnuala ; Harkin, Denis Paul ; Davison, Timothy ; Goffard, Nicolas ; Bylesjo, Max ; Proutski, Vitali ; Taggart, Laura</creator><creatorcontrib>Kennedy, Richard ; Hill, Laura A ; Deharo, Steve ; Walker, Steven ; Parkes, Eileen ; Keating, Katherine E ; O'Donnell, Jude ; Patterson, Fionnuala ; Harkin, Denis Paul ; Davison, Timothy ; Goffard, Nicolas ; Bylesjo, Max ; Proutski, Vitali ; Taggart, Laura</creatorcontrib><description>An immune response subtype of cancer is associated with DNA damage which allows subjects to be stratified for particular therapies including immune therapies which may be combined with DNA damage therapeutics. A method for predicting responsiveness to an antagonist of an inhibitory immune checkpoint and/or an agonist of a stimulatory immune checkpoint comprises determining the expression level of at least one gene selected from Table 2B, 2A or 1 in a sample from the subject. The determined expression level is used to predict responsiveness to an antagonist of an inhibitory immune checkpoint and/or an agonist of a stimulatory immune checkpoint.</description><language>eng</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS OR TEST PAPERS THEREFOR ; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ; ENZYMOLOGY ; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS ; METALLURGY ; MICROBIOLOGY ; MUTATION OR GENETIC ENGINEERING ; PROCESSES OF PREPARING SUCH COMPOSITIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2018</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20180222&DB=EPODOC&CC=AU&NR=2016295347A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20180222&DB=EPODOC&CC=AU&NR=2016295347A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Kennedy, Richard</creatorcontrib><creatorcontrib>Hill, Laura A</creatorcontrib><creatorcontrib>Deharo, Steve</creatorcontrib><creatorcontrib>Walker, Steven</creatorcontrib><creatorcontrib>Parkes, Eileen</creatorcontrib><creatorcontrib>Keating, Katherine E</creatorcontrib><creatorcontrib>O'Donnell, Jude</creatorcontrib><creatorcontrib>Patterson, Fionnuala</creatorcontrib><creatorcontrib>Harkin, Denis Paul</creatorcontrib><creatorcontrib>Davison, Timothy</creatorcontrib><creatorcontrib>Goffard, Nicolas</creatorcontrib><creatorcontrib>Bylesjo, Max</creatorcontrib><creatorcontrib>Proutski, Vitali</creatorcontrib><creatorcontrib>Taggart, Laura</creatorcontrib><title>Gene signature for immune therapies in cancer</title><description>An immune response subtype of cancer is associated with DNA damage which allows subjects to be stratified for particular therapies including immune therapies which may be combined with DNA damage therapeutics. A method for predicting responsiveness to an antagonist of an inhibitory immune checkpoint and/or an agonist of a stimulatory immune checkpoint comprises determining the expression level of at least one gene selected from Table 2B, 2A or 1 in a sample from the subject. The determined expression level is used to predict responsiveness to an antagonist of an inhibitory immune checkpoint and/or an agonist of a stimulatory immune checkpoint.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS OR TEST PAPERS THEREFOR</subject><subject>CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES</subject><subject>ENZYMOLOGY</subject><subject>MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>PROCESSES OF PREPARING SUCH COMPOSITIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2018</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNB1T81LVSjOTM9LLCktSlVIyy9SyMzNLQUKlmSkFiUWZKYWK2TmKSQn5iWnFvEwsKYl5hSn8kJpbgZlN9cQZw_d1IL8-NTigsRkoGkl8Y6hRgaGZkaWpsYm5o6GxsSpAgBbYyrd</recordid><startdate>20180222</startdate><enddate>20180222</enddate><creator>Kennedy, Richard</creator><creator>Hill, Laura A</creator><creator>Deharo, Steve</creator><creator>Walker, Steven</creator><creator>Parkes, Eileen</creator><creator>Keating, Katherine E</creator><creator>O'Donnell, Jude</creator><creator>Patterson, Fionnuala</creator><creator>Harkin, Denis Paul</creator><creator>Davison, Timothy</creator><creator>Goffard, Nicolas</creator><creator>Bylesjo, Max</creator><creator>Proutski, Vitali</creator><creator>Taggart, Laura</creator><scope>EVB</scope></search><sort><creationdate>20180222</creationdate><title>Gene signature for immune therapies in cancer</title><author>Kennedy, Richard ; Hill, Laura A ; Deharo, Steve ; Walker, Steven ; Parkes, Eileen ; Keating, Katherine E ; O'Donnell, Jude ; Patterson, Fionnuala ; Harkin, Denis Paul ; Davison, Timothy ; Goffard, Nicolas ; Bylesjo, Max ; Proutski, Vitali ; Taggart, Laura</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_AU2016295347A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2018</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS OR TEST PAPERS THEREFOR</topic><topic>CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES</topic><topic>ENZYMOLOGY</topic><topic>MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>PROCESSES OF PREPARING SUCH COMPOSITIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>Kennedy, Richard</creatorcontrib><creatorcontrib>Hill, Laura A</creatorcontrib><creatorcontrib>Deharo, Steve</creatorcontrib><creatorcontrib>Walker, Steven</creatorcontrib><creatorcontrib>Parkes, Eileen</creatorcontrib><creatorcontrib>Keating, Katherine E</creatorcontrib><creatorcontrib>O'Donnell, Jude</creatorcontrib><creatorcontrib>Patterson, Fionnuala</creatorcontrib><creatorcontrib>Harkin, Denis Paul</creatorcontrib><creatorcontrib>Davison, Timothy</creatorcontrib><creatorcontrib>Goffard, Nicolas</creatorcontrib><creatorcontrib>Bylesjo, Max</creatorcontrib><creatorcontrib>Proutski, Vitali</creatorcontrib><creatorcontrib>Taggart, Laura</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Kennedy, Richard</au><au>Hill, Laura A</au><au>Deharo, Steve</au><au>Walker, Steven</au><au>Parkes, Eileen</au><au>Keating, Katherine E</au><au>O'Donnell, Jude</au><au>Patterson, Fionnuala</au><au>Harkin, Denis Paul</au><au>Davison, Timothy</au><au>Goffard, Nicolas</au><au>Bylesjo, Max</au><au>Proutski, Vitali</au><au>Taggart, Laura</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Gene signature for immune therapies in cancer</title><date>2018-02-22</date><risdate>2018</risdate><abstract>An immune response subtype of cancer is associated with DNA damage which allows subjects to be stratified for particular therapies including immune therapies which may be combined with DNA damage therapeutics. A method for predicting responsiveness to an antagonist of an inhibitory immune checkpoint and/or an agonist of a stimulatory immune checkpoint comprises determining the expression level of at least one gene selected from Table 2B, 2A or 1 in a sample from the subject. The determined expression level is used to predict responsiveness to an antagonist of an inhibitory immune checkpoint and/or an agonist of a stimulatory immune checkpoint.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_AU2016295347A1 |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PROCESSES OF PREPARING SUCH COMPOSITIONS SPIRITS VINEGAR WINE |
| title | Gene signature for immune therapies in cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T16%3A14%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Kennedy,%20Richard&rft.date=2018-02-22&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EAU2016295347A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |